Related Experiment Videos

Expression of new phenotypic markers in cholangiocarcinoma and putative precursor lesions

M Roncalli¹, C Patriarca, M Gambacorta

¹Second Department of Pathology, University of Milan Medical School, Italy.

Journal of Surgical Oncology. Supplement

|January 1, 1993

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Advancing breast cancer clinical management through technological innovation: the potential role of artificial intelligence and integrated care models.

ESMO open·2026

Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06.

ESMO open·2025

See all related articles